Spyre Therapeutics (SYRE) Change in Receivables (2015 - 2023)
Spyre Therapeutics (SYRE) reported Change in Receivables of -$163000.0 for Q4 2023, up 44.56% on a YoY basis from -$112757.6 in Q4 2022, and up 89.01% quarter-over-quarter from -$1.5 million in Q3 2023.
Spyre Therapeutics (SYRE) Change in Receivables (2015 - 2023) Analysis & Trends
Spyre Therapeutics has reported Change in Receivables for 7 years, with the latest figure at -$163000.0 in Q4 2023.
- For the quarter ending Q4 2023, Change in Receivables rose 44.56% year-over-year to -$163000.0; the trailing twelve-month figure through Sep 2024 stood at -$163000.0 (up 67.79% YoY), and the FY2023 full-year result was -$375000.0, up 14.77% from the prior year.
- Change in Receivables for Q4 2023 stood at -$163000.0, up from -$1.5 million in the prior quarter.
- The five-year high for Change in Receivables was $21.5 million in Q1 2021, with the low at -$21.5 million in Q2 2021.
- Historically, Change in Receivables has averaged $0.0 across 3 years, with a median of -$45000.0 in 2023.
- The largest YoY upside for Change in Receivables was 346.9% in 2023 against a maximum downside of 880.53% in 2023.
- Spyre Therapeutics' Change in Receivables stood at $815000.0 in 2021, then slumped by 136.07% to -$294000.0 in 2022, then jumped by 44.56% to -$163000.0 in 2023.
- The last three Change in Receivables figures came in at -$163000.0 (Q4 2023), -$1.5 million (Q3 2023), and $1.3 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -163,000.00 |
| Dec 31, 2023 | -163,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | -45,000.00 |
| Mar 31, 2023 | -45,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Jun 30, 2021 | -21.50 Mn |
| Jun 30, 2021 | -21.50 Mn |